Limited capacity in US pediatric drug trials: qualitative analysis of expert interviews.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The recently renewed Best Pharmaceuticals for Children and Pediatric Research Equity Acts (BPCA/PREA) have continued industry incentives and opportunities for pediatric drug trials (PDTs). However, there is no current assessment of the capacity to perform PDTs.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Paediatr Drugs

Title: Paediatric drugs

Publisher: Springer Nature America, Inc

ISSN (Electronic): 1179-2019

ISSN (Print): 1174-5878

Publication date (Electronic): Apr 01 2011

Volume: 13

Issue: 2

Affiliations

[1 ] Pediatric Research in Office Settings (PROS), Department of Research, American Academy of Pediatrics, Elk Grove Village, Illinois, USA. richard.wasserman@uvm.edu

Article

Publisher Item ID: 6

DOI: 10.2165/11584240-000000000-00000

PubMed ID: 21351811

SO-VID: e61ab403-65e8-4b54-a168-af02d5b5884f

History

Data availability:

Comments

Comment on this article

scite_

Cited by 3

See all cited by